FasR antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-10053510-B2
Application number	US-201414893847-A
Country	US
Kind code	B2
Filing date	May 26, 2014
Priority date	May 24, 2013
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).

First claim

The invention claimed is:

1. An antibody or fragment thereof that binds selectively to a misfolded form of human Fas receptor (FasR), wherein the antibody or fragment thereof binds to an epitope comprising at least 5 contiguous residues of LHHDGQFCH (SEQ ID No. 2) of the misfolded human FasR, the antibody comprising a heavy chain and a light chain, each chain having a constant region and a variable region, each variable region comprising framework regions and complementarity determining regions (CDRs), wherein the CDRs comprise the amino acid sequence set forth below:
For the heavy chain:

CDR1
(SEQ ID No. 33)

CDR2
(SEQ ID No. 34)

CDR3
(SEQ ID No. 35)

For the light chain:

CDR1
(SEQ ID No. 36)

CDR2
(SEQ ID No. 37)

CDR3
(SEQ ID No. 38).

2. An antibody or binding fragment thereof according to claim 1 , wherein the light chain variable region comprises SEQ ID NO. 32 and/or wherein the heavy chain variable region comprises SEQ ID NO. 30.

3. An antibody according to claim 2 , wherein the light chain comprises SEQ ID No. 31 and/or wherein the heavy chain comprises SEQ ID No. 29.

4. A diagnostic kit comprising the antibody or binding fragment according to claim 1 or an immunoconjugate thereof, and instructions for the use thereof to detect cells presenting misfolded human FasR.

5. An immunoconjugate comprising the antibody or binding fragment according to claim 1 , conjugated with a toxin or a detectable label.

6. An immunoconjugate comprising the antibody or binding fragment defined by claim 2 conjugated to a toxin or a detectable label.

7. An immunoconjugate comprising the antibody defined by claim 3 of conjugated to a toxin or a detectable label.

8. A pharmaceutical composition comprising the antibody or binding fragment according to claim 1 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising the antibody or binding fragment of claim 2 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising the antibody of claim 3 , or an immunoconjugate thereof, and a pharmaceutically acceptable carrier.

11. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody or binding fragment according to claim 1 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.

12. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody or binding fragment according to claim 2 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.

13. A method for detecting, in a biological sample, cells that present misfolded FasR, the method comprising incubating the sample with the antibody according to claim 3 or an immunoconjugate thereof, and detecting formation of an antibody-bound complex.

Assignees

• Promis Neurosciences Inc
• Univ British Columbia

Inventors

• Uger Marni Diane
• Ciolfi Veronica
• Cashman Neil R

Classifications

• A61P37/04

  Immunostimulants · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• C07K16/2878 Primary

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title